Adagio(IVVD) - 2024 Q4 - Annual Results

Financial Performance - Invivyd, Inc. reported preliminary fourth quarter 2024 net product revenue for PEMGARDA™ (pemivibart) [4] - The company aims for near-term profitability, indicating strong revenue growth [4] - Total operating costs and expenses for the fourth quarter 2024 were also disclosed, though specific figures were not provided [4] - Cash and cash equivalents as of December 31, 2024, were included in the preliminary financial data [4] Clinical Development - Invivyd announced positive Phase 1/2 clinical data for VYD2311, a monoclonal antibody intended as a superior alternative to COVID-19 vaccination [6]